The estimated Net Worth of John B Iii Henneman is at least $6.58 million dollars as of 13 March 2024. Mr. Henneman owns over 6,860 units of Aprea Therapeutics stock worth over $26,208 and over the last 22 years he sold APRE stock worth over $6,355,301. In addition, he makes $201,489 as Lead Independent Director at Aprea Therapeutics.
John has made over 58 trades of the Aprea Therapeutics stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 6,860 units of APRE stock worth $50,009 on 13 March 2024.
The largest trade he's ever made was exercising 100,000 units of Aprea Therapeutics stock on 2 November 2010 worth over $3,025,000. On average, John trades about 5,894 units every 57 days since 2003. As of 13 March 2024 he still owns at least 8,139 units of Aprea Therapeutics stock.
You can see the complete history of Mr. Henneman stock trades at the bottom of the page.
John Bell Henneman III serves as Lead Independent Director of the Company. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation, a biotechnology company. From October 2014 to July 2018, Mr. Henneman served as Executive Vice President and Chief Financial Officer at NewLink Genetics Corporation, a biopharmaceutical company. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corp (“Integra”)., a publicly-held medical device company, in various capacities. Before becoming Integra’s Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra’s regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra’s surgical instruments business, and Integra’s business development function. Mr. Henneman currently serves on the boards of directors of R1 RCM, Inc., a publicly-held revenue cycle technology and management services company, SeaSpine Holdings Corporation, a publicly-held medical technology company, and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.
As the Lead Independent Director of Aprea Therapeutics, the total compensation of John Henneman at Aprea Therapeutics is $201,489. There are 6 executives at Aprea Therapeutics getting paid more, with Christian Schade having the highest compensation of $3,677,570.
John Henneman is 58, he's been the Lead Independent Director of Aprea Therapeutics since 2020. There are 9 older and 8 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... et John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: